These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11820060)

  • 1. [Acetylsalicylic acid in primary prevention of cardiovascular events; literature study].
    Bredie SJ; Wollersheim HC; Verheugt FW; Thien T
    Ned Tijdschr Geneeskd; 2002 Jan; 146(2):68-72. PubMed ID: 11820060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose aspirin for primary prevention of cardiovascular disease.
    Bredie SJ; Wollersheim H; Verheugt FW; Thien T
    Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
    Waltering A; Hemkens L; Florack C
    Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on aspirin in the primary prevention of cardiovascular disease.
    Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
    Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Howard G
    Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin for the prevention of cardiovascular morbidity.
    Sanchez-Ross M; Waller AH; Maher J; Klapholz M; Haider B; Kaluski E
    Minerva Med; 2010 Aug; 101(4):205-14. PubMed ID: 21030934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
    Prescrire Int; 2000 Jun; 9(47):89-90. PubMed ID: 11010752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
    Arjomand H; Cohen M; Ezekowitz MD
    J Invasive Cardiol; 2004 May; 16(5):271-8. PubMed ID: 15152137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of acetylsalicylic acid by physicians and in the community.
    Mahon J; Steel K; Feagan BG; Laupacis A; Pederson LL
    CMAJ; 1991 Nov; 145(9):1107-16. PubMed ID: 1751930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acetylsalicylic acid for the primary prevention of cardiovascular disease in diabetic patients].
    de Lange DW; Fiets WE; Banga JD
    Ned Tijdschr Geneeskd; 2004 Jul; 148(30):1481-5. PubMed ID: 15481570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events].
    Klomp CM; ten Cate H; Stehouwer CD; Schaper NC
    Ned Tijdschr Geneeskd; 2009; 153():A109. PubMed ID: 19785798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin use in the prevention of cardiovascular events.
    Crutcher JM; Mallonee S; Daniels C
    J Okla State Med Assoc; 2007 Oct; 100(10):383-7. PubMed ID: 18085095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term therapy with clopidogrel in combination with ASA significantly reduces risk of death, myocardial infarct or stroke].
    Minerva Med; 2003 Apr; 94(2):XIII-IV. PubMed ID: 12916522
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.